Pharmacogenomics

Genetic Toxicology Testing Market Report 2022: Increasing Use Of Pharmacogenomics And Personalized Medicines Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Health, Biotechnology, Pathology, Application, CRO, Charles River Laboratories, National Network, USD, Reagent, Industry, Risk, EFSA, Toxicology, Toxicity, Growth, Food, Plant, Acquisition, FDA, Contract research organization, Gene, CAGR, LabCorp, CPIC, Organization, Medical device, Pharmacogenomics

The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030.

Key Points: 
  • The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030.
  • The rising usage of personalized medicines, combined with the development of cell and gene therapy across the globe is enhancing the demand for genotoxicology.
  • Increasing implementation of pharmacogenomics to support personalized medicine usage and reduced risk of adverse drug toxicity is considered to have a significant impact on the growth of the industry.
  • Hence, these limitations are anticipated to hamper the growth of the genetic toxicology industry.

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

Retrieved on: 
Thursday, October 27, 2022
23andMe, Therapy, Securities Exchange Act of 1934, Security (finance), U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Genomic Health, Stroke, Growth, Terminology, Risk, Genotype, Cholesterol, Food, Lijun International Pharmaceutical (Holding) Co. Ltd., Sumathi Best Television Current Reporting Award, Annual report, List of Dove Medical Press academic journals, Patient, SAMS, Pharmacogenomics, SLCO1B1, GLOBE, PGT, Simvastatin, FDA, SAN, Securities Act of 1933, Drug Quality and Security Act, Genetics, Genome, Pharmaceutical industry

The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.

Key Points: 
  • The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.
  • Simvastatin is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.
  • In 2020, simvastatin was the second-most commonly prescribed statin, and the thirteenth-most commonly prescribed medication overall, in the U.S.* A variation of a particular gene, SLCO1B1, influences the bodys response to simvastatin.
  • 23andMe underwent rigorous analytical validation in order to meet FDA requirements to remove the need for confirmatory testing of the 23andMe pharmacogenetics report for SLCO1B1.

Insights on the Direct-To-Consumer Genetic Testing Global Market to 2027 - Rising Demand for Personalized Direct-To-Consumer Genetic Testing Services Will Boost the Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Health, Genetics, Technology, Prevalence, Genetic testing, Whole genome sequencing, Sample, DTC, Market share, GT, Pharmacogenomics, Industry, COVID-19, Conditional sentence, DNA, CAGR, Internet, Awareness, Global, Lists of diseases, Targeted analysis sequencing, Social media, USD, US Foods, History, Agriculture, Vaccine, Tourism

Rising demand for personalized genetic services, as well as increased public awareness around the world, are expected to aid market growth.

Key Points: 
  • Rising demand for personalized genetic services, as well as increased public awareness around the world, are expected to aid market growth.
  • The COVID-19 pandemic boosted the direct-to-consumer genetic testing market.
  • During the pandemic, technological advancements have paved the way for new business opportunities in direct-to-consumer genetic testing.
  • The shift from passive to empowered customers has created opportunities for businesses to respond in a variety of sectors, including genetic testing.

Patients Choice Laboratories Acquires Infinity Laboratories, LLC to Better Provide Complete Suite of Services to Providers in the Southern U.S.

Retrieved on: 
Tuesday, October 18, 2022
CAP, Laboratory, Infection, CLIA, Population, LLC, Patient, Pharmacogenomics, Research, Kaiser Family Foundation, PCL, Antimicrobial stewardship, Acquisition, Health, Genetic testing, GLOBE, Toxicology, Pharmaceutical industry

Infinity Laboratories is an infectious disease laboratory specializing in molecular diagnostics serving the population of north Texas.

Key Points: 
  • Infinity Laboratories is an infectious disease laboratory specializing in molecular diagnostics serving the population of north Texas.
  • The acquisition will provide PCL a location in the southern United States to bring their complete suite of testing services to the area for providers and patients.
  • Utilizing industry-leading molecular diagnostics, PCL provides precise and specific results allowing for quick diagnoses and treatment of patients within 24-hours.
  • Patients Choice Laboratories plans to begin running tests out of their newly acquired Bridgeport, Texas location in the coming weeks.

Northern Kentucky Based Company Helps Serve the Community After Devastating Natural Disasters

Retrieved on: 
Thursday, September 15, 2022
University, Disaster, CEO, GLOBE, Flood, COVID-19, Hematology, Clothing, Toxicology, EKY, Pharmacogenomics, Pharmaceutical industry

The company recently donated $50,000 to the Eastern Kentucky Flood Relief Fund to help their efforts in assisting those in need who were impacted by the devastating floods.

Key Points: 
  • The company recently donated $50,000 to the Eastern Kentucky Flood Relief Fund to help their efforts in assisting those in need who were impacted by the devastating floods.
  • Kentucky state officials have said at least 35 people died and hundreds of people were forced from their homes due to the floods.
  • The company offered an employee match donation program through the EKY fundraiser which helped raise over $4,000.
  • Gravitys dedication to Kentucky was also showcased last year when Western Kentucky was hit by devastating tornados that affected the lives of so many.

The Good Clinic Expands Services with Pharmacogenetic Testing by Xact Laboratories

Retrieved on: 
Thursday, September 8, 2022
Technology, MinuteClinic, Genetics, Arm, Time, Good, GLOBE, Good clinical laboratory practice, Pharmacogenomics, LLC, Laboratory, Acquisition, Practitioner, Patient, Pharmaceutical industry, Medicine

Minneapolis, MN, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Good Clinic™ is deepening its service offerings to include pharmacogenomic testing through Xact Laboratories, an Ohio-based biotechnology company focused on providing state-of-the-art molecular diagnostic tests. The product, XactMed4U™, can help clinicians understand how certain medications may work best for individual patients based on their unique genetics, resulting in better patient outcomes and potentially reduced costs. In alignment with the mission of providing accessible and customized health care, all The Good Clinic locations will offer the service.

Key Points: 
  • In alignment with the mission of providing accessible and customized health care, all The Good Clinic locations will offer the service.
  • Through the pharmacogenetics testing services with Xact Laboratories , The Good Clinic will have the ability to provide more accurate diagnostics and treatments for clients with behavioral health conditions.
  • Pharmacogenomics is a leading-edge technology in the healthcare industry, said The Good Clinic Chief Nurse Practitioner Officer Kevin Lee Smith.
  • Mitesco operations and subsidiaries include The Good Clinic, LLC ("The Good Clinic").

Pharmacogenomics Market Report 2022: Increased Collaborations and Product Approvals to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, Pharmaceutical, Genetics, Health, University, EGFR, University of Arizona College of Pharmacy, Division, Technology, Application, Pharmacogenomics, Large-cell lung carcinoma, Empire Genomics, Toxicity, Drug combination, OPKO Health, Genotype, Hoffmann-La Roche, Novartis, US, LLC, Banner Health, Illumina, Inc., Genome, Region, GeneDx, Thermo Fisher Scientific, Pharmacology, Decision support system, Pharmacotherapy, FDA, Cdx, Agilent Technologies, CAGR, NSCLC, Genetic variation, Neoplasm, Association for Molecular Pathology v. Myriad Genetics, Inc., Abbott Laboratories, U.S. FDA, Industry, Marketing, Adoption, Patient, Renewable energy, Pharmaceutical industry

The "Pharmacogenomics Market, by Technology, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacogenomics Market, by Technology, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Such approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup.
  • Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.
  • Key players operating in the global pharmacogenomics market are focusing on adoption of growth strategies such as collaborations and product approvals, which are expected to drive the market growth during the forecast period.

Morgan Health Announces New Investment in LetsGetChecked, Expanding Access to At-Home Health Care

Retrieved on: 
Thursday, September 8, 2022
Health Technology, Health Insurance, Health, Telemedicine, Virtual Medicine, Partnership, Patient, HIV disease progression rates, Veritas Genetics, CEO, EU, NYSE, Health minister, Pharmacogenomics, Research, LTP, Kaiser Permanente, Human resources, JPMorgan Chase, API, Emerge Commerce, Investment, Organization, Public sector, JPM, Whole genome sequencing, Prevalence, Diabetes, COVID-19, National Operating Committee on Standards for Athletic Equipment, Growth, Health, Healthcare, Pharmaceutical industry, Castlight Health

These new offerings allow LetsGetChecked to support the full lifecycle of care across womens health, mens health, sexual health as well as general health and wellness.

Key Points: 
  • These new offerings allow LetsGetChecked to support the full lifecycle of care across womens health, mens health, sexual health as well as general health and wellness.
  • Morgan Healths investment in LetsGetChecked follows its recent investments in Vera Whole Health , and subsequent investment in Castlight Health , Embold Health , Centivo and research collaboration with Kaiser Permanente .
  • Morgan Health is a JPMorgan Chase business unit focused on improving employer-sponsored health care.
  • Through its investments and the advancement of accountable care, Morgan Health is working to improve the quality, equity and affordability of employer-sponsored health care for JPMorgan Chase employees, their families and the U.S. health system.

Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million

Retrieved on: 
Friday, August 12, 2022
People, City, Outline, Laboratory, Health, ICL, Precision medicine, Fourteenth Finance Commission, Hematology, Population, Social change, Growth, Policy, National Economic Protectionism Association, Infection, Hospital, Frost, Pharmacogenomics, Molecular biology, Hospital Insurance and Diagnostic Services Act, Government, Mass spectrometry, Republic, Neoplasm, Immunoassay, Marketing, Patient, COVID-19, Biotechnology, Awareness, CAGR, Lists of diseases, Pathology, Physician, Solution, PCR, Pharmaceutical industry, Medical imaging, Medical device, Group

Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.

Key Points: 
  • Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.
  • Diagnostic testing services for medical institution alliances mainly assists leading hospitals in establishing on-site diagnosis centers covering four main types (i.e.
  • Revenue from this segment rose by 166.2% to RMB650.7 million as at the Reporting Period.
  • As of 30 June 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million, compared with a full-year average revenue of RMB2.2 million in 2021.

GenXys Extends North American Market Coverage as Global Experts Confirm Need for Tools to Enable Pharmacogenetics

Retrieved on: 
Thursday, July 28, 2022
Death, View, Interview, Insurance, United Kingdom, Laboratory, Research, ADR, Media relations, CEO, Solution, Software, Pharmacy, Population health, Patient safety, Pharmacogenomics, Multimedia, Adoption, Patient, National Health Service, Health, Pharmaceutical industry

Two of these labs use the cutting-edge Agena Bioscience MassARRAY Systemgenetic testing platform, which works seamlessly with the GenXys agnostic platform.

Key Points: 
  • Two of these labs use the cutting-edge Agena Bioscience MassARRAY Systemgenetic testing platform, which works seamlessly with the GenXys agnostic platform.
  • GenXys recently solidified deals with three North American laboratory companies for its precision prescribing solutions.
  • Additionally, at a recent GenXys webinar , Professor Sir Munir Pirmohamed said: "I don't see pharmacogenetics as something that is going to be static.
  • GenXys' clinical decision support software suite is in use by major insurance providers, health systems, and pharmacies across North America.